Advances in and the potential of vaccines for respiratory syncytial virus
- PMID: 23964629
- DOI: 10.1586/17476348.2013.814409
Advances in and the potential of vaccines for respiratory syncytial virus
Abstract
Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory track illness causing bronchiolitis and some mortality in infants and the elderly. Despite decades of research there is no licensed RSV vaccine. To enable the development of RSV vaccines, several major obstacles must be overcome including immature and waning immunity to RSV infection, the capacity of RSV to evade immunity and the failure of RSV infection to induce robust enduring immunity. Since the failure of the formalin-inactivated RSV vaccine trial, more cautious and deliberate progress has been made toward RSV vaccine development using a variety of experimental approaches. The scientific rational and the state of development of these approaches are reviewed in this article.
Similar articles
-
Immunopathology of RSV infection: prospects for developing vaccines without this complication.Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518. Rev Med Virol. 2007. PMID: 17004293 Review.
-
Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.Vaccine. 2012 Jan 11;30(3):597-606. doi: 10.1016/j.vaccine.2011.11.054. Epub 2011 Nov 24. Vaccine. 2012. PMID: 22120195
-
Subunit and virus-like particle vaccine approaches for respiratory syncytial virus.Curr Top Microbiol Immunol. 2013;372:285-306. doi: 10.1007/978-3-642-38919-1_14. Curr Top Microbiol Immunol. 2013. PMID: 24362695 Review.
-
Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.J Infect Dis. 2004 Dec 1;190(11):1936-40. doi: 10.1086/425516. Epub 2004 Oct 28. J Infect Dis. 2004. PMID: 15529257 Clinical Trial.
-
The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Expert Rev Vaccines. 2012 Dec;11(12):1441-57. doi: 10.1586/erv.12.117. Expert Rev Vaccines. 2012. PMID: 23252388 Review.
Cited by
-
Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.Molecules. 2024 Jan 25;29(3):598. doi: 10.3390/molecules29030598. Molecules. 2024. PMID: 38338343 Free PMC article. Review.
-
An Interaction of LPS and RSV Infection in Augmenting the AHR and Airway Inflammation in Mice.Inflammation. 2017 Oct;40(5):1643-1653. doi: 10.1007/s10753-017-0604-7. Inflammation. 2017. PMID: 28695368
-
Respiratory Syncytial Virus-Infected Mesenchymal Stem Cells Regulate Immunity via Interferon Beta and Indoleamine-2,3-Dioxygenase.PLoS One. 2016 Oct 3;11(10):e0163709. doi: 10.1371/journal.pone.0163709. eCollection 2016. PLoS One. 2016. PMID: 27695127 Free PMC article.
-
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.Yonsei Med J. 2016 Jul;57(4):809-16. doi: 10.3349/ymj.2016.57.4.809. Yonsei Med J. 2016. PMID: 27189271 Free PMC article. Review.
-
Respiratory syncytial virus induces phosphorylation of mTOR at ser2448 in CD8 T cells from nasal washes of infected infants.Clin Exp Immunol. 2016 Feb;183(2):248-57. doi: 10.1111/cei.12720. Epub 2015 Nov 24. Clin Exp Immunol. 2016. PMID: 26437614 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical